VERAXA Biotech pushes ahead with BiTAC cancer platform after NASDAQ listing

By Vivian Lin · September 24, 2026, 8:46 AM · 3 mins read

VERAXA Biotech has joined the NASDAQ and is moving fast on its oncology pipeline built around the BiTAC platform. The Swiss company is entering a new phase.

VERAXA Biotech (NASDAQ: VRXA) is not waiting around. The Swiss biotech has put its future on the BiTAC(R) platform, a dual-component cancer therapy it developed in-house. Now, after merging with Voyager Acquisition Corp.—a SPAC backed by Cantor Fitzgerald—VERAXA has landed on the NASDAQ Capital Market. The company started trading as VRXA on June 11, 2026, according to independent market reports.

VERAXA’s move to the U.S. public markets wrapped up in June. The deal included a $27.5 million senior secured note and a securities purchase agreement. This gives VERAXA the cash it needs to speed up its drug programs. An official SEC regulatory filing shows the note runs for about 15 months, with monthly payments starting roughly three months after closing.

In September 2026, VERAXA confirmed it is advancing a portfolio based on the BiTAC platform, including both bi-specific ADC and TCE formats, as well as several engineered antibody programs in its oncology pipeline.

BiTAC sits at the core of VERAXA’s plan. It’s an “AND-gated” therapy that needs two matching components to hit the same cancer cell before it can kill it. This setup is meant to make the treatment more targeted and cut down on side effects—a problem that has dogged cancer drugs for years. VERAXA has shared early preclinical data for both BiTAC-TCE and BiTAC-ADC. In June 2026, the company announced an in-vitro proof of concept for BiTAC-ADC. Independent market coverage called this a key step in showing the platform works.

VERAXA is also working on other antibody-drug conjugates and engineered antibody projects, adding more depth to its cancer pipeline. In September 2026, Raju Willener joined as chief financial officer, bringing over 30 years of experience in capital markets and corporate finance. Christoph Erkel, Ph.D., is chief scientific officer. Company statements say Willener started right away, showing VERAXA wants to boost its financial and strategic execution.

Going public is more than just a funding move for VERAXA. It marks a push to grow its cancer drug ambitions and use BiTAC as a way to stand out in a crowded field. Now, the company has to turn early lab results into real clinical progress, all while public investors and U.S. biotech rivals watch closely. With its two-part approach and new leadership, VERAXA is aiming to be a player in next-generation cancer drugs. The real test will be whether its science can deliver on the promise that comes with new funding and a public spotlight.

In September 2026, independent market news reported that VERAXA's VXA-222 bispecific antibody-drug conjugate advanced to its next development stage after completing an initial collaboration phase with OmniAb, highlighting ongoing expansion of the company's antibody engineering and intellectual property portfolio.

MarketMinuteMarket News Summary

Topics:

Biotechnology Newsroom

Vivian Lin

Vivian Lin is Biotech Markets & Transactions Editor at GenoMethods, covering licensing agreements, M&A, biotech financing, company pipelines, strategic partnerships and cross-border transactions. Her reporting connects deal structure and company strategy with the scientific and clinical evidence underlying each biotechnology asset.